CRISPR Therapeutics
CRSP
CRSP
444 hedge funds and large institutions have $3.47B invested in CRISPR Therapeutics in 2022 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 170 increasing their positions, 97 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
444
Holders Change
–
Holders Change %
0%
% of All Funds
7.03%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
72
Increased
170
Reduced
97
Closed
65
Calls
$149M
Puts
$156M
Net Calls
-$6.94M
Net Calls Change
-$24M
Top Buyers
| 1 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$290M |
| 2 |
BlackRock
New York
|
+$63.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.3M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.5M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$81.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$31.9M |
| 3 |
Jennison Associates
New York
|
-$31M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$28.5M |
| 5 |
Millennium Management
New York
|
-$21.3M |
